89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging in Pancreatic Cancer or Other CA19-9 Positive Malignancies
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Zirconium 89 5B1 (Primary) ; MVT 5873
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics
- 19 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2024 Planned End Date changed from 1 May 2024 to 1 May 2025.
- 11 Jan 2024 Planned primary completion date changed from 1 May 2024 to 1 May 2025.